(Total Views: 558)
Posted On: 02/04/2021 4:41:12 PM
Post# of 155791
Re: MD VIROLOGIST #76217
BMS-813160 is a walking, talking advertisement for leronlimab.
Google "BMS-813160" and you find the reason for existence of leronlimab as to CCR5.
BMS-813160 also blocks CCR2 so it does have that going for it.
But like the other small molecule antagonists, it is probably toxic at some level.
BMS-813160 is currently in human trials both as a monotherapay and a combo therapy with Bristol Meyers Squib franchise Opdivo.
One nice thing about leronlimab approval for covid is that many Opdivo patients will receive leronlimab, although probably not for long enough to discern any effect.
I wonder what work CYDY has done towards combo trials with existing approved PD1 immunotherapies.
I did not think that pancreatic cancer was a candidate for leronlimab.
LL cancer applications require CCR5 overexpression, I thought.
Maybe some pancreatic cancers overexpres CCR5? Maybe all?
Google "BMS-813160" and you find the reason for existence of leronlimab as to CCR5.
BMS-813160 also blocks CCR2 so it does have that going for it.
But like the other small molecule antagonists, it is probably toxic at some level.
BMS-813160 is currently in human trials both as a monotherapay and a combo therapy with Bristol Meyers Squib franchise Opdivo.
One nice thing about leronlimab approval for covid is that many Opdivo patients will receive leronlimab, although probably not for long enough to discern any effect.
I wonder what work CYDY has done towards combo trials with existing approved PD1 immunotherapies.
I did not think that pancreatic cancer was a candidate for leronlimab.
LL cancer applications require CCR5 overexpression, I thought.
Maybe some pancreatic cancers overexpres CCR5? Maybe all?
(4)
(0)
